Conference Call with Hester Biosciences Management and Analysts on Q3FY24 Performance and Outlook. Listen to the full earnings transcript.
Pharmaceuticals company Hester Biosciences announced Q2FY24 & H1FY24 results: 1. Financial Performance: Q2FY24: Revenue from Operations: Rs 704.55 crore, down 4% YoY EBITDA: Rs 132.12 crore, up 4% YoY Profit after Tax (excl. OCI): Rs 40.41 crore, down 39% YoY Earnings Per Share (EPS): Rs 4.75, down 39% YoY H1FY24: Revenue from Operations: Rs 1,583.08 crore, up 28% YoY EBITDA: Rs 275.75 crore, up 37% YoY Profit after Tax (excl. OCI): Rs 107.51 crore, up 6% YoY Earnings Per Share (EPS): Rs 12.64, up 6% YoY 2. Division Performance: - Animal Healthcare division experienced a 16% decline in sales in Q2FY24 due to uneven sales of the Goat Pox Vaccine. - Poultry Healthcare division saw a 4% decrease in overall sales in Q2FY24, with a growth in domestic vaccine sales, but a reduction in export sales. - Petcare division achieved impressive performance, growing 98% in Q2FY24. 3. Subsidiary Performance: - Hester Nepal had a turnover of Rs 7.28 million in Q2FY24, primarily from domestic sales of vaccines, with an overall net loss of Rs 7.05 million. - Hester Africa continued export sales but faced an overall loss of Rs 49.17 million due to foreign exchange fluctuations. - Hester's share of profit in the joint venture entity, Thrishool Exim Limited (Tanzania), increased by 9.86 million in Q2FY24. Result PDF
Conference Call with Hester Biosciences Management and Analysts on Q4FY23 Performance and Outlook. Listen to the full earnings transcript.
Pharmaceuticals company Hester Biosciences announced Q4FY23 & FY23 results: Standalone Q4FY23 & FY23: Overall gross profit margin reduced by 1% due to the change in product mix between vaccines and health products, health products sales having gone up. Operating EBITDA increased with the increase in sales. The reduction in EBITDA margin was due to the reduction in Gross Profit margin, accompanied by higher market development costs in animal health division and the new pet division Q4 PAT margin benefited from lower finance costs due to the reversal of unrealized forex loss of Rs 6.46 million on the translation of USD loan in Q4FY23, as against a loss of Rs 5.31 million in Q4FY22. Consequently, PAT increased by 27% from Rs 49.48 million to Rs 62.63 million. Result PDF